Marker Therapeutics (MRKR) Stock Price, News & Analysis

Company Overview

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Key Stats

• Today's Range: $1.17 to $1.29
• 50-Day Range: $1.18 to $2.75
• 52-Week Range: $1.13 to $5.99
• Volume: 58,165 shs
• Average Volume: 58,043 shs
• Market Capitalization: $12.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Buy

Marker Therapeutics Stock Analysis - MarketRank™

Marker Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 196th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Marker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Marker Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.65) to ($2.19) per share.

Price to Book Value per Share Ratio

Marker Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.93% of the float of Marker Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Marker Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Marker Therapeutics has recently decreased by 7.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Marker Therapeutics does not currently pay a dividend.

Dividend Growth

Marker Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -0.75

Percentage of Shares Shorted

1.93% of the float of Marker Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Marker Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Marker Therapeutics has recently decreased by 7.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Marker Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.50% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.39% of the stock of Marker Therapeutics is held by institutions.

MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed this year?

Marker Therapeutics' stock was trading at $3.11 at the beginning of the year. Since then, MRKR shares have decreased by 61.7% and is now trading at $1.19.
View the best growth stocks for 2025 here.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 89.63% and a negative net margin of 179.74%.

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' top institutional investors include NEA Management Company LLC (15.18%), Alyeska Investment Group L.P. (8.55%), Blue Owl Capital Holdings LP (5.18%) and Aisling Capital Management LP (3.04%).
View institutional ownership trends.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 3/25/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRKR
• CIK: 1094038
• Web: www.markertherapeutics.com
• Phone: (713) 400-6400
• Fax: N/A
• Employees: 60
• Year Founded: 2018

Price Target and Rating

• Average Stock Price Target: $13.50
• High Stock Price Target: $19.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +1,034.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,240,000.00
• Net Margins: -179.74%
• Pretax Margin: -178.50%
• Return on Equity: -89.63%
• Return on Assets: -71.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.15
• Quick Ratio: 3.15

Sales & Book Value

• Annual Sales: $3.31 million
• Price / Sales: 3.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.58 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 10,709,000
• Free Float: 9,156,000
• Market Cap: $12.74 million
• Optionable: Not Optionable
• Beta: 1.51